penitentiary [1%):<25 mg/dL)> <1% (Limited to important or life-threatening): Confusion, hypersensitivity reaction (including hypersensitivity angiitis, pruritus, severe hypersensitivity, skin rash, urticaria), memory impairment Warnings/Precautions Concerns related to adverse effects: Hypersensitivity reactions: Hypersensitivity reactions, including some severe reactions requiring hospitalization (eg, hypersensitivity vasculitis), have been reported. Discontinue treatment and initiate supportive treatment in patients who develop serious allergic reaction. Other hypersensitivity reactions, including pruritus, rash, and urticaria, have been reported. Monitoring Parameters LDL-C within 4 to 8 weeks of initiation or dose titration. For patients receiving 300 mg every 4 weeks, measure LDL-C just prior to the next scheduled dose (LDL-C varies considerably between doses with this regimen). Monitor for hypersensitivity reactions. Pregnancy Considerations Adverse events were not observed in animal reproduction studies. Information specific to alirocumab in pregnancy is not available. However, IgG molecules are known to cross the placenta, with increasing amounts during the second and third trimesters of pregnancy. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience rhinitis, pharyngitis, injection site pain, itching or irritation, or flu-like symptoms (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating, and advising patients. Next Pregnancy Warnings Print this page Add to My Med List More about alirocumab Side Effects During Pregnancy Dosage Information Support Group En Español 31 Reviews Add your own review/rating Drug class: PCSK9 inhibitors Consumer resources Alirocumab Alirocumab Subcutaneous (Advanced Reading) Professional resources Alirocumab (AHFS Monograph) Other brands: Praluent Related treatment guides Cardiovascular Risk Reduction High Cholesterol High Cholesterol, Familial Heterozygous High Cholesterol, Familial Homozygous> ] Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Alirocumab Rating 31 User Reviews 6.6 /10 31 User Reviews 6.6 Rate it! Drug Class PCSK9 inhibitors Related Drugs PCSK9 inhibitors Repatha , Praluent , evolocumab , Repatha Pushtronex High Cholesterol, Familial Heterozygous atorvastatin , simvastatin , Crestor , Lipitor , pravastatin , Zocor , More... High Cholesterol, Familial Homozygous atorvastatin , simvastatin , Crestor , Lipitor , Zocor , rosuvastatin , More... Cardiovascular Risk Reduction simvastatin , Zocor , ramipril , Victoza , telmisartan , Altace , More... 1 more conditions... it is important
most appropriate Alirocumab and cannot
EmoticonEmoticon